Talking Techniques | CAR-T and CAR-NK cell therapies
In this episode of Talking Techniques, Ritwika Biswas, Field Scientist at Sino Biological US Inc. (PA, USA), walks us through the chimeric antigen receptor (CAR) development process and how T and natural killer (NK) cells can be utilized to carry these modular synthetic molecules. Ritwika also addresses the safety and efficacy of these cell therapies as well as the ethical considerations around them.
Contents:
- Introduction: 00:00–01:22
- An introduction to CAR-T therapy: 01:22–04:03
- What is CAR-NK therapy and how does it differ from CAR-T therapy? 04:03–05:57
- How are CARs developed? 05:57–09:28
- What are the advantages of CAR-T and CAR-NK therapies? 09:28–12:45
- What are the disadvantages? 12:45–16:30
- How can we improve the safety and efficacy of these cell therapies? 16:30–18:25
- What are the ethical considerations? 18:25–22:06
- Are there any other applications of CAR-T therapy besides cancer? 22:06–24:44
- Summary and future perspectives: 24:44–27:35
This feature was supported by Sino Biological.
